940310-85-0 Usage
Description
NVP-BHG712 is a small molecule inhibitor that targets multiple kinases, including EphB4, VEGFR2, c-raf, c-src, and c-Abl, with ED50 values ranging from 25 nM to 1.7 μM.
Used in Pharmaceutical Industry:
NVP-BHG712 is used as a kinase inhibitor for the biological study and therapeutic use of combinations of kinase inhibitors in treating colorectal cancer. Its ability to target multiple kinases makes it a promising candidate for cancer treatment, as it can potentially inhibit multiple signaling pathways involved in tumor growth and progression.
Biochem/physiol Actions
NVP-BHG712 is a very potent, selective inhbitor of the receptor tyrosine kinase EphB4 (ED50 = 25 nM). NVP-BHG712 blocks Ephrin receptor autophosphorylation and VEGF-induced angiogenesis.
references
[1]. martiny-baron, g., et al., the small molecule specific ephb4 kinase inhibitor nvp-bhg712 inhibits vegf driven angiogenesis. angiogenesis, 2010. 13(3): p. 259-67.[2]. kathawala, r.j., et al., the small molecule tyrosine kinase inhibitor nvp-bhg712 antagonizes abcc10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. oncotarget, 2015. 6(1): p. 510-21.[3]. becerikli, m., et al., ephb4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma. int j cancer, 2015. 136(8): p. 1781-91.
Check Digit Verification of cas no
The CAS Registry Mumber 940310-85-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,0,3,1 and 0 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 940310-85:
(8*9)+(7*4)+(6*0)+(5*3)+(4*1)+(3*0)+(2*8)+(1*5)=140
140 % 10 = 0
So 940310-85-0 is a valid CAS Registry Number.
940310-85-0Relevant articles and documents
SUBSTITUTED PENTA-FUSED HEXA-HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, DRUG COMBINATION AND USE THEREOF
-
Paragraph 0282; 0295-0297; 0317; 0326, (2020/06/16)
A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS
-
Page/Page column 58, (2010/11/27)
The invention relates to novel pyrazolo[3,4-d]pyrimidines of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
